DK2421879T3 - Nye 7-deazapurinnukleotider til terapeutiske anvendelser - Google Patents

Nye 7-deazapurinnukleotider til terapeutiske anvendelser

Info

Publication number
DK2421879T3
DK2421879T3 DK10734433.5T DK10734433T DK2421879T3 DK 2421879 T3 DK2421879 T3 DK 2421879T3 DK 10734433 T DK10734433 T DK 10734433T DK 2421879 T3 DK2421879 T3 DK 2421879T3
Authority
DK
Denmark
Prior art keywords
new
therapeutic applications
deazapurine nucleotides
deazapurine
nucleotides
Prior art date
Application number
DK10734433.5T
Other languages
Danish (da)
English (en)
Inventor
Aurelie Bourderioux
Michal Hocek
Petr Naus
Original Assignee
Acad Of Science Czech Republic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acad Of Science Czech Republic filed Critical Acad Of Science Czech Republic
Application granted granted Critical
Publication of DK2421879T3 publication Critical patent/DK2421879T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14Pyrrolo-pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK10734433.5T 2009-04-22 2010-04-19 Nye 7-deazapurinnukleotider til terapeutiske anvendelser DK2421879T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17165609P 2009-04-22 2009-04-22
PCT/CZ2010/000050 WO2010121576A2 (en) 2009-04-22 2010-04-19 Novel 7-deazapurine nucleosides for therapeutic uses

Publications (1)

Publication Number Publication Date
DK2421879T3 true DK2421879T3 (da) 2013-11-25

Family

ID=42768153

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10734433.5T DK2421879T3 (da) 2009-04-22 2010-04-19 Nye 7-deazapurinnukleotider til terapeutiske anvendelser

Country Status (15)

Country Link
US (3) US9321800B2 (https=)
EP (1) EP2421879B1 (https=)
JP (2) JP5721275B2 (https=)
CN (2) CN102459300B (https=)
AU (3) AU2010238985B2 (https=)
CA (2) CA2966647A1 (https=)
DK (1) DK2421879T3 (https=)
ES (1) ES2437917T3 (https=)
HR (1) HRP20131021T1 (https=)
MX (1) MX2011011160A (https=)
NZ (2) NZ700583A (https=)
PL (1) PL2421879T3 (https=)
PT (1) PT2421879E (https=)
SI (1) SI2421879T1 (https=)
WO (1) WO2010121576A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459300B (zh) * 2009-04-22 2014-12-10 捷克有机化学和生物化学研究院 用于治疗用途的新的7-脱氮嘌呤核苷
AU2010330823A1 (en) * 2009-12-18 2012-07-05 Joslin Diabetes Center, Inc. Beta-cell replication promoting compounds and methods of their use
CN102319254B (zh) * 2011-07-20 2013-06-19 上海交通大学 5-碘代杀菌核素在制备抗肿瘤药物中的应用
CZ305466B6 (cs) * 2013-11-04 2015-10-14 Ústav organické chemie a biochemie Akademie věd České republiky, v. v. i. Substituované 7-deazapurinové ribonukleosidy pro terapeutické použití
ES2792036T3 (es) 2014-11-14 2020-11-06 Nerviano Medical Sciences Srl Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de cinasa
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CA3029170C (en) 2016-06-29 2021-02-16 Ustav Organicke Chemie A Biochemie Av Cr, V.V.I. Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
EP4717317A2 (en) 2017-06-20 2026-04-01 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
US11072628B2 (en) 2017-10-19 2021-07-27 Universiteit Gent Nucleoside analogues for the treatment of parasitic infections
WO2019143991A1 (en) * 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
WO2020033288A1 (en) * 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
MX2021015772A (es) * 2019-06-18 2022-01-31 Taiho Pharmaceutical Co Ltd Compuesto de carbonato novedoso que tiene esqueleto de pirrolopirimidina o sal farmaceuticamente aceptable del mismo.
WO2021164848A1 (en) * 2020-02-17 2021-08-26 Katholieke Universiteit Leuven Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments
KR102639275B1 (ko) * 2021-06-08 2024-02-21 퓨쳐메디신 주식회사 다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물
WO2023052468A1 (en) 2021-09-28 2023-04-06 Universiteit Antwerpen Nucleoside analogues for the treatment of parasitic infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
WO2002057425A2 (en) * 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2002353165A1 (en) * 2001-12-17 2003-06-30 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
AU2003232071A1 (en) * 2002-05-06 2003-11-17 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
US20040157892A1 (en) 2003-02-12 2004-08-12 Crompton Co./Cie Pesticidal fluoroethyl pyrazoles
JP2007509939A (ja) * 2003-10-27 2007-04-19 ジェネラブズ テクノロジーズ インコーポレーティッド ウイルス感染を治療するためのヌクレオシド化合物
US7202223B2 (en) * 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
EP1682564A1 (en) * 2003-10-27 2006-07-26 Genelabs Technologies, Inc. METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D|PYRIMIDINE DERIVATIVES
EP1781101A2 (en) * 2004-07-29 2007-05-09 Metabasis Therapeutics, Inc. Novel nucleoside derivatives
CN101977923B (zh) * 2008-01-18 2014-10-08 捷克有机化学和生物化学研究院 抑制细胞生长的7-脱氮嘌呤核苷
NZ590005A (en) * 2008-06-23 2012-06-29 Janssen Pharmaceutica Nv Piperidyl acrylamide antogonists of ccr2
GB0815968D0 (en) * 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
CN102459300B (zh) * 2009-04-22 2014-12-10 捷克有机化学和生物化学研究院 用于治疗用途的新的7-脱氮嘌呤核苷

Also Published As

Publication number Publication date
CA2759131A1 (en) 2010-10-28
CN104497084A (zh) 2015-04-08
AU2015205885B2 (en) 2017-04-06
US20150218201A1 (en) 2015-08-06
EP2421879B1 (en) 2013-09-04
JP5721275B2 (ja) 2015-05-20
CN102459300B (zh) 2014-12-10
NZ700583A (en) 2016-04-29
US9321800B2 (en) 2016-04-26
US10294262B2 (en) 2019-05-21
NZ596301A (en) 2014-10-31
HK1209129A1 (en) 2016-03-24
CN104497084B (zh) 2018-06-05
AU2017204148A1 (en) 2017-07-06
AU2015205885A1 (en) 2015-09-03
US9624257B2 (en) 2017-04-18
ES2437917T3 (es) 2014-01-15
CA2966647A1 (en) 2010-10-28
AU2017204148B2 (en) 2018-12-06
AU2010238985A1 (en) 2011-12-01
JP6087889B2 (ja) 2017-03-01
WO2010121576A3 (en) 2011-06-16
PL2421879T3 (pl) 2014-02-28
US20160318970A1 (en) 2016-11-03
HRP20131021T1 (hr) 2014-01-31
CA2759131C (en) 2017-06-20
SI2421879T1 (sl) 2014-01-31
EP2421879A2 (en) 2012-02-29
HK1166325A1 (en) 2012-12-14
PT2421879E (pt) 2013-12-09
CN102459300A (zh) 2012-05-16
JP2012524731A (ja) 2012-10-18
JP2015013901A (ja) 2015-01-22
US20170240584A1 (en) 2017-08-24
MX2011011160A (es) 2012-01-27
AU2010238985B2 (en) 2015-04-23
WO2010121576A2 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
DK2421879T3 (da) Nye 7-deazapurinnukleotider til terapeutiske anvendelser
CY2020008I2 (el) Φαρμακοτεχνικες μορφες διστρωματικου δισκιου
SMT201700095B (is) Composizioni farmaceutiche per inalazione
SMT201700008B (it) Composizione farmaceutica
DK2408807T3 (da) Fremgangsmåde til terapeutisk anvendelse
DK3097925T3 (da) Farmaceutisk sammensætning
BRPI1004940A2 (pt) composição farmacêutica
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
EP2509515A4 (en) WITHERS
ATE557381T1 (de) Präsentationssäule
DK3246018T3 (da) Farmaceutisk sammensætning
SMT201400069B (it) Formulazione farmaceutica
BRPI1015939A2 (pt) composição farmacêutica
EE201300005A (et) Ravimkoostis
DK2399606T3 (da) Fremgangsmåde til fremstilling af varmebestandig oxygenbærerholdig farmaceutisk sammensætning
FI20106109A0 (fi) Pilarikenkä
FI20106110A0 (fi) Pilarikenkä
BRPI1014688A2 (pt) aplicações terapêuticas de derivados de quinazolinadiona
UY33111A (es) Jeringas
EP2615946A4 (en) ADJUSTABLE CHILD SEAT
BR112013015097A2 (pt) coluna de perfuração
FR2959228B1 (fr) Nucleotides modifies
BR112012003149A2 (pt) composição farmacêutica
BRPI1009033A2 (pt) sistema terapêutico
BR112012029461A2 (pt) composição farmacêutica contendo solifenacina